EFTRライブシグナル | Getagraph.comで利益を最大化

売る 109347 min ago

@ $11.19

発行日: 14 2月 2024 @ 00:58

リターン: -82.62%

Live Chart Being Loaded With Signals

Commentary (29 4月 2024 @ 23:15):

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer...

Stats
本日の出来高	23 482.00
平均出来高	382 382
時価総額	7.17M
EPS	$-3.42 ( 2024-03-27 )
次の収益日	( $-2.17 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.120
ATR14	$0.0250 (1.29%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-19	Loewy Caroline M	Buy	2 000	Stock Option (Right to Buy)
2024-02-19	Bhatt Elizabeth	Buy	2 000	Stock Option (Right to Buy)
2024-02-19	Ehrlich Christopher B	Buy	2 000	Stock Option (Right to Buy)
2024-02-19	Klencke Barbara	Buy	2 000	Stock Option (Right to Buy)
2024-02-19	Harrington-smith Kristen	Buy	2 000	Stock Option (Right to Buy)

INSIDER POWER
45.06
Last 95 transactions
Buy: 5 541 401 \| Sell: 1 016 887

ボリューム相関

長: -0.16 (neutral)

短: -0.14 (neutral)

Signal:(49.752) Neutral

eFFECTOR Therapeutics, 相関

10 最も正の相関
APOP	0.91
FLGT	0.875
PIII	0.875
PRSR	0.871
MAGS	0.871
SOFIW	0.867
CMLF	0.867
LPTX	0.864
AGCUU	0.863
WKSP	0.863

10 最も負の相関
ULTA	-0.855
IEP	-0.845
TNDM	-0.833
IART	-0.83
ASO	-0.829
CDAK	-0.828
IQ	-0.827
PAYS	-0.827
SBNYP	-0.817
PHCF	-0.815

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

eFFECTOR Therapeutics, 相関 - 通貨/商品

0.32
( neutral )

0.42
( neutral )

0.00
( neutral )

0.46
( neutral )

0.64
( weak )

-0.44
( neutral )

eFFECTOR Therapeutics, 財務諸表

Annual	2023
収益:	$0
総利益:	$-111 000 (0.00 %)
EPS:	$-16.37

FY	2023
収益:	$0
総利益:	$-111 000 (0.00 %)
EPS:	$-16.37

FY	2022
収益:	$3.55M
総利益:	$3.50M (98.51 %)
EPS:	$-7.85

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$1.050

Financial Reports:

No articles found.

eFFECTOR Therapeutics,

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.